Organon & Co. (NYSE:OGN) & Basel Medical Group (NASDAQ:BMGL) Head to Head Analysis

Organon & Co. (NYSE:OGN) and Basel Medical Group (NASDAQ:BMGL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Risk and Volatility

Organon & Co. has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Basel Medical Group has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Organon & Co. and Basel Medical Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organon & Co.	5	1	0	1	1.57
Basel Medical Group	1	0	0	0	1.00

Organon & Co. presently has a consensus price target of $8.50, indicating a potential upside of 33.77%. Given Organon & Co.’s stronger consensus rating and higher possible upside, research analysts clearly believe Organon & Co. is more favorable than Basel Medical Group.

Institutional & Insider Ownership

77.4% of Organon & Co. shares are owned by institutional investors. 2.0% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Organon & Co. and Basel Medical Group”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organon & Co.	$6.22 billion	0.27	$187.00 million	$0.71	8.95
Basel Medical Group	$8.90 million	1.28	-$9.50 million	N/A	N/A

Organon & Co. has higher revenue and earnings than Basel Medical Group.

Profitability

This table compares Organon & Co. and Basel Medical Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Organon & Co.	3.01%	122.01%	6.74%
Basel Medical Group	N/A	N/A	N/A

Summary

Organon & Co. beats Basel Medical Group on 11 of the 12 factors compared between the two stocks.

About Organon & Co.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

About Basel Medical Group

Basel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.